Moderna Says European Patent Office Decided To Maintain Validity Of Co's EP949 Patent, One Of The Key Patents Currently Asserted Against Pfizer & BioNTech In Various European National Courts
Portfolio Pulse from Benzinga Newsdesk
Moderna announced that the European Patent Office has decided to maintain the validity of its EP949 patent. This patent is one of the key patents currently asserted against Pfizer and BioNTech in various European national courts.
May 17, 2024 | 4:09 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
BioNTech faces a legal challenge as the European Patent Office upholds the validity of Moderna's EP949 patent, which is a key element in the ongoing litigation with Moderna.
The decision by the European Patent Office to uphold the EP949 patent strengthens Moderna's legal claims against BioNTech, potentially leading to negative legal and financial consequences for BioNTech.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
The European Patent Office's decision to maintain the validity of Moderna's EP949 patent is a setback for Pfizer, which is currently involved in legal disputes with Moderna over this patent.
The decision negatively impacts Pfizer's legal position in its disputes with Moderna, potentially leading to unfavorable outcomes in ongoing and future litigation.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
The European Patent Office's decision to maintain the validity of Moderna's EP949 patent strengthens Moderna's legal position against Pfizer and BioNTech.
The decision by the European Patent Office to uphold the EP949 patent is a significant legal win for Moderna, potentially enhancing its competitive position and intellectual property rights.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100